Blog
Sarepta Files Two IPRs Against Genzyme’s Patents Related to Gene Therapy Elevidys®
On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to the characterization of recombinant adeno-associated virus (rAAV) vector preparations….
By: Venable LLP